Brokers

Leerink Partnrs Brokers Boost Earnings Estimates for AlloVir, Inc. (NASDAQ:ALVR)


AlloVir, Inc. (NASDAQ:ALVRFree Report) – Equities researchers at Leerink Partnrs lifted their Q1 2024 earnings per share (EPS) estimates for shares of AlloVir in a research note issued on Monday, March 18th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($0.15) for the quarter, up from their previous estimate of ($0.18). Leerink Partnrs has a “Market Perform” rating on the stock. The consensus estimate for AlloVir’s current full-year earnings is ($0.45) per share. Leerink Partnrs also issued estimates for AlloVir’s Q2 2024 earnings at ($0.03) EPS, Q3 2024 earnings at ($0.03) EPS, FY2024 earnings at ($0.24) EPS and FY2025 earnings at $0.00 EPS.

ALVR has been the topic of several other research reports. Bank of America downgraded AlloVir from a “buy” rating to an “underperform” rating in a research note on Tuesday, December 26th. JPMorgan Chase & Co. cut AlloVir from an “overweight” rating to an “underweight” rating in a report on Friday, December 22nd. SVB Leerink cut AlloVir from an “outperform” rating to a “market perform” rating in a report on Friday, December 22nd. Finally, Piper Sandler cut AlloVir from an “overweight” rating to a “neutral” rating in a report on Friday, December 22nd. Two research analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, AlloVir has an average rating of “Hold” and an average target price of $18.67.

Check Out Our Latest Report on ALVR

AlloVir Trading Up 1.9 %

Shares of ALVR opened at $0.75 on Wednesday. The business’s 50 day moving average is $0.71 and its 200 day moving average is $1.43. The company has a market capitalization of $85.67 million, a PE ratio of -0.41 and a beta of 0.85. AlloVir has a 12-month low of $0.62 and a 12-month high of $6.12.

Hedge Funds Weigh In On AlloVir

A number of large investors have recently bought and sold shares of the business. Swiss National Bank raised its position in AlloVir by 7.5% during the 1st quarter. Swiss National Bank now owns 84,800 shares of the company’s stock valued at $572,000 after purchasing an additional 5,900 shares in the last quarter. JPMorgan Chase & Co. raised its position in AlloVir by 27.7% during the 1st quarter. JPMorgan Chase & Co. now owns 763,908 shares of the company’s stock valued at $5,157,000 after purchasing an additional 165,711 shares in the last quarter. MetLife Investment Management LLC raised its position in AlloVir by 51.5% during the 1st quarter. MetLife Investment Management LLC now owns 18,052 shares of the company’s stock valued at $122,000 after purchasing an additional 6,136 shares in the last quarter. BlackRock Inc. raised its position in AlloVir by 2.9% during the 1st quarter. BlackRock Inc. now owns 2,230,919 shares of the company’s stock valued at $15,059,000 after purchasing an additional 62,747 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of AlloVir by 43.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 70,387 shares of the company’s stock worth $476,000 after acquiring an additional 21,337 shares in the last quarter. Hedge funds and other institutional investors own 47.41% of the company’s stock.

Insider Transactions at AlloVir

In other news, CEO Diana Brainard sold 41,421 shares of AlloVir stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $0.67, for a total value of $27,752.07. Following the completion of the transaction, the chief executive officer now owns 822,321 shares in the company, valued at approximately $550,955.07. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In the last 90 days, insiders sold 103,830 shares of company stock worth $69,465. 39.97% of the stock is currently owned by company insiders.

About AlloVir

(Get Free Report)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

See Also



Receive News & Ratings for AlloVir Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AlloVir and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.


    Input this code: captcha